Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease

Experimental Cell Research

Volumn 318, Issue 9, 2012, Pages 1040-1048

  Quarles, L Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

1,25(OH)2D; Bone; Calcium; Cyp24; Cyp27b1; Kidney; Klotho; Osteoblasts; Osteocytes

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CHRONIC KIDNEY DISEASE; HUMAN; NONHUMAN; OSTEOLYSIS; PATHOGENESIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VITAMIN D METABOLISM;

EID: 84859852194     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.02.027     Document Type: Review

References (105)

1. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 2006, 91:3144-3149.
2. Bai X., Miao D., Li J., Goltzman D., Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004, 145:5269-5279.
3. Beckman M.J., Tadikonda P., Werner E., Prahl J., Yamada S., DeLuca H.F. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996, 35:8465-8472.
4. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., Sirkis R., Naveh-Many T., Silver J. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
5. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro O.M., Mohammadi M., Sirkis R., Naveh-Many T., Silver J. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
6. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005, 14:385-390.
7. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004, 15:2208-2218.
8. Brown W.W., Juppner H., Langman C.B., Price H., Farrow E.G., White K.E., McCormick K.L. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J. Clin. Endocrinol. Metab. 2009, 94:17-20.
9. Burnett S.A., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 2006, 21:1187-1196.
10. Clemens T.L., Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J. Bone Miner. Res. 2011, 26:677-680.
11. Craver L., Marco M.P., Martinez I., Rue M., Borras M., Martin M.L., Sarro F., Valdivielso J.M., Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007, 22:1171-1176.
12. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., Yu X., Rauch F., Davis S.I., Zhang S., Rios H., Drezner M.K., Quarles L.D., Bonewald L.F., White K.E. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006, 38:1310-1315.
13. Ferrari S.L., Bonjour J.P., Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 2005, 90:1519-1524.
14. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., Ritz E., Kronenberg F., Kuen E., Konig P., Kraatz G., Mann J.F., Muller G.A., Kohler H., Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007, 18:2600-2608.
15. Fukumoto S., Yamashita T. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr. Opin. Nephrol. Hypertens. 2002, 11:385-389.
16. Galitzer, H., Ben-Dov, I.Z., Silver, J., and Naveh-Many, T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77: 211-218.
17. Goebel S., Lienau J., Rammoser U., Seefried L., Wintgens K.F., Seufert J., Duda G., Jakob F., Ebert R. FGF23 is a putative marker for bone healing and regeneration. J. Orthop. Res. 2009.
18. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., Juppner H., Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 2005, 16:2205-2215.
19. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., Smith K., Lee H., Thadhani R., Juppner H., Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008, 359:584-592.
20. Hasegawa H., Nagano N., Urakawa I., Yamazaki Y., Iijima K., Fujita T., Yamashita T., Fukumoto S., Shimada T. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010, 78:975-980.
21. Helvig C.F., Cuerrier D., Hosfield C.M., Ireland B., Kharebov A.Z., Kim J.W., Ramjit N.J., Ryder K., Tabash S.P., Herzenberg A.M., Epps T.M., Petkovich M. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 2010, 78:463-472.
22. Hirai T., Chagin A.S., Kobayashi T., Mackem S., Kronenberg H.M. Parathyroid hormone/parathyroid hormone-related protein receptor signaling is required for maintenance of the growth plate in postnatal life. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:191-196.
23. Hoenderop J.G., Chon H., Gkika D., Bluyssen H.A., Holstege F.C., St-Arnaud R., Braam B., Bindels R.J. Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1 alpha-hydroxylase knockout mice. Kidney Int. 2004, 65:531-539.
24. Hu M.C., Shi M., Zhang J., Pastor J., Nakatani T., Lanske B., Shawkat Razzaque M., Rosenblatt K.P., Baum M.G., Kuro O.M., Moe O.W. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010.
25. Imanishi Y., Inaba M., Nakatsuka K., Nagasue K., Okuno S., Yoshihara A., Miura M., Miyauchi A., Kobayashi K., Miki T., Shoji T., Ishimura E., Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004, 65:1943-1946.
26. Isakova T., Gutierrez O.M., Smith K., Epstein M., Keating L.K., Juppner H., Wolf M. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2010, 26:584-591.
27. Jean G., Bresson E., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., Mayor B., Chazot C. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol. Dial. Transplant. 2009, 24:948-955.
28. Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B., Bennett E.P., Mandel U., Strom T.M., Clausen H. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 2006, 281:18370-18377.
29. Kawata T., Imanishi Y., Kobayashi K., Miki T., Arnold A., Inaba M., Nishizawa Y. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 2007, 18:2683-2688.
30. Kobayashi K., Imanishi Y., Koshiyama H., Miyauchi A., Wakasa K., Kawata T., Goto H., Ohashi H., Koyano H.M., Mochizuki R., Miki T., Inaba M., Nishizawa Y. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006, 78:2295-2301.
31. Kobayashi K., Imanishi Y., Miyauchi A., Onoda N., Kawata T., Tahara H., Goto H., Miki T., Ishimura E., Sugimoto T., Ishikawa T., Inaba M., Nishizawa Y. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur. J. Endocrinol. 2006, 154:93-99.
32. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., Sugimura K., Kishimoto T., Kinoshita S., Kuroki T., Nabeshima Y. Severely reduced production of klotho in human chronic renal failure kidney. Biochem. Biophys. Res. Commun. 2001, 280:1015-1020.
33. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., Collins J.F., Haussler M.R., Ghishan F.K. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G1036-G1042.
34. Komaba H., Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010, 77:292-298.
35. Kuro-o M. Klotho. Pflugers Arch. 2010, 459:333-343.
36. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y.I. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
37. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K.P., Baum M.G., Schiavi S., Hu M.C., Moe O.W., Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281:6120-6123.
38. Larsson T., Davis S.I., Garringer H.J., Mooney S.D., Draman M.S., Cullen M.J., White K.E. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 2005, 146:3883-3891.
39. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., Juppner H., Jonsson K.B. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004, 145:3087-3094.
40. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003, 64:2272-2279.
41. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 2010, 299:F882-F889.
42. Li H., Martin A., David V., Quarles L.D. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am. J. Physiol. Endocrinol. Metab. 2011, 300:E508-E517.
43. Li H., Martin A.C., David V., Quarles L.D. Compound deletion of FGFR3 and FGFR4 partially rescues the Hyp mouse phenotype. Am. J. Physiol. Endocrinol. Metab. 2010, E508-E517.
44. Li S.A., Watanabe M., Yamada H., Nagai A., Kinuta M., Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 2004, 29:91-99.
45. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 2003, 278:37419-37426.
46. Liu S., Quarles L.D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 2007, 18:1637-1647.
47. Liu S., Rowe P.S., Vierthaler L., Zhou J., Quarles L.D. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J. Endocrinol. 2007, 192:261-267.
48. Liu S., Tang W., Fang J., Ren J., Li H., Xiao Z., Quarles L.D. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol. Endocrinol. 2009, 23:1505-1518.
49. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., Quarles L.D. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 2006, 17:1305-1315.
50. Liu S., Vierthaler L., Tang W., Zhou J., Quarles L.D. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J. Am. Soc. Nephrol. 2008, 19:2342-2350.
51. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E38-E49.
52. Mirams M., Robinson B.G., Mason R.S., Nelson A.E. Bone as a source of FGF23: regulation by phosphate?. Bone 2004, 35:1192-1199.
53. Mirza M.A., Alsio J., Hammarstedt A., Erben R.G., Michaelsson K., Tivesten A., Marsell R., Orwoll E., Karlsson M.K., Ljunggren O., Mellstrom D., Lind L., Ohlsson C., Larsson T.E. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler. Thromb. Vasc. Biol. 2011, 31:219-227.
54. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006, 69:1945-1953.
55. Moe S.M., Zidehsarai M.P., Chambers M.A., Jackman L.A., Radcliffe J.S., Trevino L.L., Donahue S.E., Asplin J.R. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 6:257-264.
56. Nagano N., Miyata S., Abe M., Kobayashi N., Wakita S., Yamashita T., Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006, 69:531-537.
57. Nishida Y., Taketani Y., Yamanaka-Okumura H., Imamura F., Taniguchi A., Sato T., Shuto E., Nashiki K., Arai H., Yamamoto H., Takeda E. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006, 70:2141-2147.
58. O'Neill W.C., Lomashvili K.A. Recent progress in the treatment of vascular calcification. Kidney Int. 2010, 78:1232-1239.
59. Oliveira R.B., Cancela A.L., Graciolli F.G., Dos Reis L.M., Draibe S.A., Cuppari L., Carvalho A.B., Jorgetti V., Canziani M.E., Moyses R.M. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin. J. Am. Soc. Nephrol. 2010, 5:286-291.
60. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146:5358-5364.
61. Quarles L.D. The bone and beyond: 'dem bones' are made for more than walking. Nat. Med. 2011, 17:428-430.
62. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J. Clin. Invest. 2008, 118:3820-3828.
63. Quarles L.D. Evidence for a bone-kidney axis regulating phosphate homeostasis. J. Clin. Invest. 2003, 112:642-646.
64. Quarles L.D., Drezner M.K. Effects of etidronate-mediated suppression of bone remodeling on aluminum-induced de novo bone formation. Endocrinology 1992, 131:122-126.
65. Razzaque M.S., St-Arnaud R., Taguchi T., Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol. Dial. Transplant. 2005, 20:2032-2035.
66. Rhee Y. FGF23 gene expression is upregulated by PTH receptor activation in osteocytes in vitr and in vivo: a parathyroid-bone link influencing the endocrine function of osteocytes. J Bone Miner Res ASBMR 31st Annual Meeting 2009, A09001860.
67. Rhee Y., Allen M.R., Condon K., Lezcano V., Ronda A.C., Galli C., Olivos N., Passeri G., O'Brien C.A., Bivi N., Plotkin L.I., Bellido T. PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling. J. Bone Miner. Res. 2010, 26:1035-1046.
68. Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L.I., White K.E., Bellido T. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011, 49:636-643.
69. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., Bianco P., Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003, 112:683-692.
70. Rosen C.J. Clinical practice. Vitamin D insufficiency. N. Engl. J. Med. 2011, 364:248-254.
71. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., Cundy J., Navvab S., Chen D., Drezner M.K., Quarles L.D., Mundy G.R. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004, 34:303-319.
72. Saito H., Maeda A., Ohtomo S., Hirata M., Kusano K., Kato S., Ogata E., Segawa H., Miyamoto K., Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 2005, 280:2543-2549.
73. Saji F., Shigematsu T., Sakaguchi T., Ohya M., Orita H., Maeda Y., Ooura M., Mima T., Negi S. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am. J. Physiol. Renal Physiol. 2010, 299:F1212-F1217.
74. Saji F., Shiizaki K., Shimada S., Okada T., Kunimoto K., Sakaguchi T., Hatamura I., Shigematsu T. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009, 111:59-66.
75. Samadfam R., Richard C., Nguyen-Yamamoto L., Bolivar I., Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009, 150:4835-4845.
76. Sato T., Tominaga Y., Ueki T., Goto N., Matsuoka S., Katayama A., Haba T., Uchida K., Nakanishi S., Kazama J.J., Gejyo F., Yamashita T., Fukagawa M. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am. J. Kidney Dis. 2004, 44:481-487.
77. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., Fukumoto S., Tomizuka K., Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
78. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fujita T., Fukumoto S., Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6500-6505.
79. Shimada T., Takeshita Y., Murohara T., Sasaki K., Egami K., Shintani S., Katsuda Y., Ikeda H., Nabeshima Y., Imaizumi T. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 2004, 110:1148-1155.
80. Shimada T., Yamazaki Y., Takahashi M., Hasegawa H., Urakawa I., Oshima T., Ono K., Kakitani M., Tomizuka K., Fujita T., Fukumoto S., Yamashita T. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 2005, 289:F1088-F1095.
81. Shore E.M., Ahn J., Jan de Beur S., Li M., Xu M., Gardner R.J., Zasloff M.A., Whyte M.P., Levine M.A., Kaplan F.S. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N. Engl. J. Med. 2002, 346:99-106.
82. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., Juppner H., Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004, 23:421-432.
83. Sitara D., Razzaque M.S., St-Arnaud R., Huang W., Taguchi T., Erben R.G., Lanske B. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 2006, 169:2161-2170.
84. Stubbs J., Liu S., Quarles L.D. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin. Dial. 2007, 20:302-308.
85. Stubbs J.R., Idiculla A., Slusser J., Menard R., Quarles L.D. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J. Am. Soc. Nephrol. 2009.
86. Stubbs J.R., Quarles L.D. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?. Nephrol. News Issues 2009, 23(33-34):36-37.
87. Takeshita K., Fujimori T., Kurotaki Y., Honjo H., Tsujikawa H., Yasui K., Lee J.K., Kamiya K., Kitaichi K., Yamamoto K., Ito M., Kondo T., Iino S., Inden Y., Hirai M., Murohara T., Kodama I., Nabeshima Y. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 2004, 109:1776-1782.
88. Tebben P.J., Singh R.J., Clarke B.L., Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin. Proc. 2004, 79:1508-1513.
89. Tentori F., Hunt W.C., Stidley C.A., Rohrscheib M.R., Bedrick E.J., Meyer K.B., Johnson H.K., Zager P.G. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006, 70:1858-1865.
90. Tomiyama K., Maeda R., Urakawa I., Yamazaki Y., Tanaka T., Ito S., Nabeshima Y., Tomita T., Odori S., Hosoda K., Nakao K., Imura A. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1666-1671.
91. Tsuji K., Maeda T., Kawane T., Matsunuma A., Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D(3) synthesis in leptin-deficient ob/ob mice. J. Bone Miner. Res. 2010, 25:1711-1723.
92. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
93. Uzum A.K., Salman S., Telci A., Boztepe H., Tanakol R., Alagol F., Ozbey N.C. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur. J. Endocrinol. 2010, 163:825-831.
94. van de Graaf S.F., Boullart I., Hoenderop J.G., Bindels R.J. Regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1alpha,25-dihydroxy Vitamin D3 and dietary Ca2+. J. Steroid Biochem. Mol. Biol. 2004, 89-90:303-308.
95. van Husen M., Fischer A.K., Lehnhardt A., Klaassen I., Moller K., Muller-Wiefel D.E., Kemper M.J. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 2010, 78:200-206.
96. Vervloet M.G., van Ittersum F.J., Buttler R.M., Heijboer A.C., Blankenstein M.A., Ter Wee P.M. Effects of dietary phosphate and calcium intake on Fibroblast Growth Factor-23. Clin. J. Am. Soc. Nephrol. 2010.
97. Weber T.J., Liu S., Indridason O.S., Quarles L.D. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 2003, 18:1227-1234.
98. Wetmore J.B., Liu S., Krebill R., Menard R., Quarles L.D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 2009.
99. Wetmore J.B., Quarles L.D. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. Nat. Clin. Pract. Nephrol. 2009, 5:24-33.
100. Wetmore J.B., Santos P.W., Mahnken J.D., Krebill R., Menard R., Gutta H., Quarles L.D. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J. Clin. Endocrinol. Metab. 2011, 96:E57-E64.
101. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001, 60:2079-2086.
102. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. Soc. Nephrol. 2010, 21:1427-1435.
103. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 2000, 277:494-498.
104. Young E.W., Akiba T., Albert J.M., McCarthy J.T., Kerr P.G., Mendelssohn D.C., Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004, 44:34-38.
105. Yu X., Ibrahimi O.A., Goetz R., Zhang F., Davis S.I., Garringer H.J., Linhardt R.J., Ornitz D.M., Mohammadi M., White K.E. Analysis of the biochemical mechanisms for the endocrine actions of Fibroblast Growth Factor-23. Endocrinology 2005, 146:4647-4656.